AMENDMENTS TO THE CLAIMS

1-27. (Canceled)

28. (Currently Amended) A compound of the formula (I),

$$\begin{array}{c|c}
\hline
 & & \\
\hline$$

their derivatives, their stereoisomers[[,]] and their pharmaceutically acceptable salts and their pharmaceutically acceptable compositions;

wherein Ar₁ represents a unsubstituted or substituted monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic structure, which may optionally contain up to 3 heteroatoms selected from N, S or O, such as

which when substituted may have up to 4 substituents that may be identical or different, wherein said substituents selected from halo, nitro, alkyl, hydroxy, hydroxyalkyl, alkoxy, thioalkoxy, oxo, aryl, --NR¹R², --OCONR¹R², NR¹COOR², --NR¹SO₂R², NR¹CONR¹R², --OSO₂R³, --SO₂R³;

R¹ and R² independently represent hydrogen, or optionally substituted groups selected from alkyl, alkenyl, alkynyl, cylcoalkyl, heterocyclyl, aryl, heteroaryl; R³ independently represents hydrogen, or optionally substituted groups selected from alkyl, alkenyl, alkynyl, cylcoalkyl, heterocyclyl, aryl, heteroaryl, wherein said substituents on R¹, R² and R³ are selected from hydrogen, halo, nitro, amino, mono or di substituted amino, hydroxy, alkoxy, carboxy, cyano, alkyl, cycloalkyl, alkoxy, haloalkoxy, haloalkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl;

m-and-n independently represents an integer from 0 to 6; m independently represents an integer from 1 to 6;

A represents O, S or a bond;

Y is selected from $(CH_2)_p$, $(CH_2)_pB(CH_2)_q$, $(CH_2)_rB(CH_2)_pD(CH_2)_q$, wherein p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR^4 or a bond, R^4 represents hydrogen, alkyl, alkenyl, --S(O)₂- R^8 or --

C(O)R⁸, R⁸ is alkyl, alkoxy; with the proviso that when B and D represents a hetero atom p is not zero;

R⁵ and R⁶ independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R⁵ and R⁶ together may form 3-8 membered cyclic ring which may optionally contains one or two hetero atoms selected from O, S or N;

R⁷ represents hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkenyl or alkynyl; wherein said substituents are selected from hydrogen, halo, nitro, amino, mono or di substituted amino, hydroxy, alkoxy, carboxy, cyano, alkyl, cycloalkyl, alkoxy, haloalkoxy, haloalkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl.

29. (Previously Presented) A compound of formula (Ia)

$$(Ia)$$

$$Ar_1 \longrightarrow B \longrightarrow (CH_2)_p \longrightarrow N \longrightarrow I \longrightarrow (CH_2)_m \longrightarrow R^6 \longrightarrow COOR^7$$

wherein all of the symbols are as defined in claim 28.

- 30. (Original) The compound of claim 29, wherein Ar_1 is substituted with $-OSO_2R^3$, and R^3 is alkyl or aryl.
- 31. (Previously Presented) The compound of formula (Ia) as claimed in claim 29 is selected from

Structure	IUPAC Name
O.S.O. H. OMe	(S)-Ethyl 2-methoxy-3- [4-{6-methanesulfonyloxynapth-2-ylmethylamino} phenyl] propanoate
O. O. O. H. OEt	Ethyl 2-ethoxy-3- [4-{6-methanesulfonyloxynapth-2-ylmethylamino} phenyl] propanoate
O O H	Ethyl 2-ethoxy-5- [4-{6-methanesulfonyloxynapth-2-ylmethylamino} phenyl] pentanoate
O O H OME	(S)-2-methoxy-3- [4-{6- methanesulfonyloxynapth-2- ylmethylamino} phenyl] propanoic acid
O O O O O O O O O O O O O O O O O O O	2-ethoxy-3- [4-{6-methanesulfonyloxynapth-2-ylmethylamino} phenyl] propanoic acid
O O O O O O O O O O O O O O O O O O O	2-Ethoxy-5- [4-{6- methanesulfonyloxynapth-2- ylmethylamino} phenyl] pentatonic acid


32 - 34. (Cancelled.)

35. (Previously Presented) The compound of formula (Ia) as claimed in claim 29 is selected from

Structure	IUPAC Name
,	
Q. COO H ₂ N H OMe	(S)-2-methoxy-3- [4-{6-methanesulfonyloxynapth-2-ylmethylamino} phenyl] propanoic acid Arginine salt
Q, cO H ₂ N H ₂ CO ₂ H N ₁ H ₂ CO ₂ H N ₁ H ₂ N ₁ H ₂	2-Ethoxy-5- [4-{6-methanesulfonyl oxynapth-2-ylmethylamino} phenyl] pentatonic acid Arginine salt
OEI ONH2 NH2 NH2	2-ethoxy-3- [4-{(6-methanesulfonyloxy-1, 2, 3, 4-tetrahydronapth-2-yl) methylamino} phenyl] propanoic acid Arginine salt
O. S. O. H. DEI GNH2 O. S. O. H. DEI GNH2	2-ethoxy-3- [4-{3-(6-methanesulfonyloxy-1, 2,3,4-tetrahydronapth-2-yl) propylamino} phenyl] propanoic acid Arginine salt
CO ₂ H OEI ⊕NH ₂	2-ethoxy-3- [4-{3-(1, 2, 3, 4-tetrahydroquinolyn-1-yl) propylamino} phenyl] propanoic acid Arginine salt

36 - 62. (Cancelled.)

63. (Currently Amended) A pharmaceutical composition, which comprises a compound of formula (I)



as defined in claim 28 and a pharmaceutically acceptable carrier, diluent, <u>or</u> excipient or solvate.

64. (Currently Amended) The A pharmaceutical composition comprising the compound of claim 30 and a pharmaceutically acceptable carrier, diluent or excipient. ef claim 63, wherein the compound is as claimed in claim[[s]] 30.

65 – 69. (Cancelled.)

70. (Original) A pharmaceutical composition as claimed in claim 63, in the form of a tablet, capsule, powder, syrup, solution or suspension.

71 - 76. (Cancelled.)

77. (New) The compound of formula (la) as claimed in claim 29 selected from

Structure	IUPAC Name
Me S O H	CO ₂ Et Ethyl 2-ethoxy-3- [4-{(6-methanesulfonyloxy-1, 2, 3, 4-tetrahydronapth-2-yl) methylamino} phenyl] propanoate
O O N H	CO ₂ Et Ethyl 2-ethoxy-3- [4-{3-(6-methanesulfonyloxy-1, 2, 3, 4-tetrahydronapth-2-yl) propylamino} phenyl] propanoate OEt
O O O O O O O O O O O O O O O O O O O	. 2-ethoxy-3- [4-{(6-methanesulfonyloxy-1, 2, 3, 4-tetrahydronapth-2-yl) methylamino} phenyl] propanoic acid
Me No Control of the	CO ₂ H 2-ethoxy-3- [4-{3-(6-methanesulfonyloxy-1, 2, 3, 4- (etrallychroizepth-2-yl) propylamino} phenyl] propunoic soid OEt